TG Therapeutics TGTX (Seite 43)
eröffnet am 13.07.20 10:32:08 von
neuester Beitrag 06.05.24 23:08:41 von
neuester Beitrag 06.05.24 23:08:41 von
Beiträge: 470
ID: 1.327.694
ID: 1.327.694
Aufrufe heute: 0
Gesamt: 38.044
Gesamt: 38.044
Aktive User: 0
ISIN: US88322Q1085 · WKN: A1JXW7 · Symbol: TGTX
16,620
USD
-0,78 %
-0,130 USD
Letzter Kurs 11.05.24 Nasdaq
Neuigkeiten
01.05.24 · globenewswire  |
30.04.24 · globenewswire |
18.04.24 · globenewswire |
18.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8700 | -12,62 | |
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies
Relative reductions of approximately 60% and 50% in ARR over teriflunomide were observed in ULTIMATE I & II, respectively
Detailed data presentation targeted in 1H 2021 with a BLA submission targeted mid-year 2021
Conference call to be held today, Thursday, December 10, 2020 at 8:30 AM ET
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial). Ublituximab treatment resulted in an ARR of <0.10 in each of ULTIMATE I & II, with a relative reduction in ARR of approximately 60% and 50%, respectively, over teriflunomide.
The ULTIMATE I & II studies investigated the safety and efficacy of a one-hour 450mg infusion of ublituximab every six months, following the Day 1 infusion (150mg over four hours). The studies were conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Further analyses of the ULTIMATE I & II studies including safety and secondary endpoints will be conducted and detailed data will be presented at an upcoming medical congress, targeted in first half of 2021. Additionally, data from these studies are intended to support a Biologics License Application (BLA) submission for ublituximab in RMS targeted in mid-year 2021.
Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University and Global Study Chair for the ULTIMATE I & II studies commented, “B-cell targeted therapy with anti-CD20 monoclonal antibodies has dramatically shifted the treatment paradigm for patients with MS and has shown to be very effective in reducing relapses in patients. I am pleased to see such positive results from this important trial exploring a one-hour infusion of ublituximab every six months and believe, if approved, the unique attributes of ublituximab, particularly that it has been glycoengineered for enhanced antibody dependent cellular cytotoxicity, may offer benefits to patients in the RMS treatment paradigm.” Dr. Steinman continued, “MS is a chronic demyelinating disease where having a variety of treatment options within the same class has shown to be important for patients. I look forward to the full data from the ULTIMATE studies to further understand the potential of ublituximab in MS.”
Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “We are so pleased to share these positive topline results for our ULTIMATE MS studies. If approved, ublituximab has the potential to offer patients a one-hour infusion, which we believe will be an attractive option for many patients with MS. With more than 1,000,000 Americans estimated to be living with MS today, there continues to be a need for efficacious and convenient treatment options.” Mr. Weiss continued, “We want to thank the patients, caregivers, doctors and research teams who participated in these studies, as well as the TG team for their efforts in helping to achieve this important milestone. We look forward to a detailed presentation of the data at a major medical meeting in the first half of 2021 once the full data are analyzed, as well as completing a BLA submission targeted for mid-next year.”
Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies
Relative reductions of approximately 60% and 50% in ARR over teriflunomide were observed in ULTIMATE I & II, respectively
Detailed data presentation targeted in 1H 2021 with a BLA submission targeted mid-year 2021
Conference call to be held today, Thursday, December 10, 2020 at 8:30 AM ET
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial). Ublituximab treatment resulted in an ARR of <0.10 in each of ULTIMATE I & II, with a relative reduction in ARR of approximately 60% and 50%, respectively, over teriflunomide.
The ULTIMATE I & II studies investigated the safety and efficacy of a one-hour 450mg infusion of ublituximab every six months, following the Day 1 infusion (150mg over four hours). The studies were conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Further analyses of the ULTIMATE I & II studies including safety and secondary endpoints will be conducted and detailed data will be presented at an upcoming medical congress, targeted in first half of 2021. Additionally, data from these studies are intended to support a Biologics License Application (BLA) submission for ublituximab in RMS targeted in mid-year 2021.
Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University and Global Study Chair for the ULTIMATE I & II studies commented, “B-cell targeted therapy with anti-CD20 monoclonal antibodies has dramatically shifted the treatment paradigm for patients with MS and has shown to be very effective in reducing relapses in patients. I am pleased to see such positive results from this important trial exploring a one-hour infusion of ublituximab every six months and believe, if approved, the unique attributes of ublituximab, particularly that it has been glycoengineered for enhanced antibody dependent cellular cytotoxicity, may offer benefits to patients in the RMS treatment paradigm.” Dr. Steinman continued, “MS is a chronic demyelinating disease where having a variety of treatment options within the same class has shown to be important for patients. I look forward to the full data from the ULTIMATE studies to further understand the potential of ublituximab in MS.”
Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “We are so pleased to share these positive topline results for our ULTIMATE MS studies. If approved, ublituximab has the potential to offer patients a one-hour infusion, which we believe will be an attractive option for many patients with MS. With more than 1,000,000 Americans estimated to be living with MS today, there continues to be a need for efficacious and convenient treatment options.” Mr. Weiss continued, “We want to thank the patients, caregivers, doctors and research teams who participated in these studies, as well as the TG team for their efforts in helping to achieve this important milestone. We look forward to a detailed presentation of the data at a major medical meeting in the first half of 2021 once the full data are analyzed, as well as completing a BLA submission targeted for mid-next year.”
Antwort auf Beitrag Nr.: 65.940.201 von opportoni am 03.12.20 19:42:59denke ich auch. Im Fall einer Übernahme dürften >50 $ drin sein.
Antwort auf Beitrag Nr.: 65.939.571 von bcgk am 03.12.20 18:53:46Absolut! Hoffe, dass wir da sogar kurzfristig, also bis zum PDUFA ankommen.
Trading Spotlight
Haltet ihr $50 für ein realistisches Kursziel?
Antwort auf Beitrag Nr.: 65.935.665 von bcgk am 03.12.20 14:33:13
Zum Glück ist TGTX durch die sehr überzeugenden P3-Studien deutlich derisked 😉
Zitat von bcgk: Falls es kein Onconova 2.0 bzgl. der Daten gibt
Zum Glück ist TGTX durch die sehr überzeugenden P3-Studien deutlich derisked 😉
Antwort auf Beitrag Nr.: 65.935.623 von opportoni am 03.12.20 14:31:09Falls es kein Onconova 2.0 bzgl. der Daten gibt 
Antwort auf Beitrag Nr.: 65.933.916 von bcgk am 03.12.20 12:25:15Du bist noch immer rechtzeitig für MS Daten und das PDUFA für MZL am 15.2.
Überall tummeln sich die gleichen Halunken
Wollte hier gerade einen Thread eröffnen und musste feststellen, dass ich hier sehr spät zur Party erscheine
Gestern Einstieg zu ~ $27.
Wollte hier gerade einen Thread eröffnen und musste feststellen, dass ich hier sehr spät zur Party erscheine
Gestern Einstieg zu ~ $27.
Durchsuchen
